Protocol Ledger

NCT04104893 · Phase II · ACTIVE NOT RECRUITING

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Interventional Phase II clinical trial protocol NCT04104893 sponsored by VA Office of Research and Development in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-20 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04104893
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04104893
Protocol FieldVerified Registry Value
NCT IdentifierNCT04104893
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2020-02-20
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI